Brief: The Sparx Group Enters Into A Collaboration With Arovella Therapeutics For The Development Of Cldn18.2-Car-Inkt Cell Therapy
10/10/2023 18:34
Oct 10 (Reuters) - SparX Group:
* THE SPARX GROUP ENTERS INTO A COLLABORATION WITH AROVELLA
THERAPEUTICS FOR THE DEVELOPMENT OF CLDN18.2-CAR-INKT CELL
THERAPY
Source text for Eikon: ID:nPn9skT68a
Further company coverage: ALA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO